![cover image](https://wikiwandv2-19431.kxcdn.com/_next/image?url=https://upload.wikimedia.org/wikipedia/commons/thumb/b/b6/Viloxazine_structure.svg/640px-Viloxazine_structure.svg.png&w=640&q=50)
Viloxazine
Medication used to treat ADHD / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Viloxazine?
Summarize this article for a 10 year old
Viloxazine, sold under the brand name Qelbree among others, is a selective norepinephrine reuptake inhibitor medication which is used in the treatment of attention deficit hyperactivity disorder (ADHD) in children and adults.[1][5] It was marketed for almost 30 years as an antidepressant for the treatment of depression before being discontinued and subsequently repurposed as a treatment for ADHD.[6][5][1] Viloxazine is taken orally.[1] It was used as an antidepressant in an immediate-release form and is used in ADHD in an extended-release form,[6][1] latterly with comparable effectiveness to atomoxetine and methylphenidate.[7][8][9]
![]() | |
![]() | |
Clinical data | |
---|---|
Trade names | Qelbree, others |
Other names | ICI-58834; SPN-812; SPN-809 |
License data |
|
Routes of administration | By mouth |
Drug class | Antidepressant; Norepinephrine reuptake inhibitor |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | 76–82%[1] |
Metabolism | Hydroxylation (CYP2D6), glucuronidation (UGT1A9, UGT2B15)[1] |
Metabolites | 5-Hydroxyviloxazine glucuronide[1] |
Elimination half-life | IR: 2–5 hours[2] ER: 7.02 ± 4.74 hours[1] |
Excretion | Urine (~90%), feces (<1%)[1][3] |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
DrugBank |
|
ChemSpider | |
UNII |
|
KEGG | |
ChEBI | |
ChEMBL |
|
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.051.148 ![]() |
Chemical and physical data | |
Formula | C13H19NO3 |
Molar mass | 237.299 g·mol−1 |
3D model (JSmol) | |
Chirality | Racemic mixture |
| |
| |
![]() ![]() |
Side effects of viloxazine include insomnia, headache, somnolence, fatigue, nausea, vomiting, decreased appetite, dry mouth, constipation, irritability, increased heart rate, and increased blood pressure.[1] Rarely, the medication may cause suicidal thoughts and behaviors.[1] It can also activate mania or hypomania in people with bipolar disorder.[1] Viloxazine acts as a selective norepinephrine reuptake inhibitor (NRI).[6][1][5] The immediate-release form has an elimination half-life of 2.5 hours[6][2] while the half-life of the extended-release form is 7 hours.[1]
Viloxazine was first described by 1972[10] and was marketed as an antidepressant in Europe in 1974.[6][11] It was not marketed in the United States at this time.[12] The medication was discontinued in 2002 for commercial reasons.[6][13][14] However, it was repurposed for the treatment of ADHD and was reintroduced, in the United States, in April 2021.[6][15][16] Viloxazine is a non-stimulant medication; it has no known misuse liability and is not a controlled substance.[1]